Discover

CTXR
Citius Pharmaceuticals, Inc.
0.61
2 x 0.44
2 x 0.76
bid
ask
+
0.00
0.73%
2 @ 04:00 PM
0.61 +0.00 (0.18%)
Ytd-21.63%
1y-67.95%
0.58
day range
0.63
0.48
52 week range
2.48
Open0.58Prev Close0.60Low0.58High0.63Mkt Cap16.72M
Vol337.63KAvg Vol631.68KEPS-2.14P/EN/AForward P/E15.32
Beta1.66Short Ratio1.23Inst. Own13.17%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1450-d Avg0.63200-d Avg0.931yr Est54.00
Income Statement
Total Revenue1.67M
Revenues (USD)1.67M
Cost of Revenue328.88K
Gross Profit1.34M
Operating Expenses33.53M
Research and Development Expense1.63M
Selling, General and Administrative Expense26.39M
Operating Income-32.19M
Interest Expense33.03K
Income Tax Expense-231.21K
Net Income-21.23M
Net Income Common Stock-21.23M
Net Income Common Stock (USD)-21.23M
Consolidated Income-28.11M
Net Income to Non-Controlling Interests-6.88M
Earnings per Basic Share-0.95
Earnings per Basic Share (USD)-0.95
Earnings per Diluted Share-0.95
Earning Before Interest & Taxes (EBIT)-21.43M
Earning Before Interest & Taxes (USD)-21.43M
Weighted Average Shares22.38M
Weighted Average Shares Diluted22.38M
Balance Sheet
Cash and Equivalents4.63M
Cash and Equivalents (USD)4.63M
Trade and Non-Trade Receivables1.08M
Current Assets31.69M
Property, Plant & Equipment Net794.52K
Total Assets132.54M
Debt Current171.50K
Total Debt808.16K
Current Liabilities55.02M
Debt Non-Current636.67K
Total Liabilities63.46M
Accumulated Retained Earnings (Deficit)-268.26M
Shareholders Equity61.54M
Shareholders Equity (USD)61.54M
Assets Non-Current100.85M
Total Debt (USD)808.16K
Goodwill and Intangible Assets9.35M
Inventory22.66M
Liabilities Non-Current8.44M
Trade and Non-Trade Payables27.10M
Tax Liabilities7.80M
Cash Flow
Depreciation, Amortization & Accretion40.66K
Net Cash Flow from Financing-1.23M
Net Cash Flow / Change in Cash & Cash Equivalents-3.13M
Capital Expenditure-600.00K
Issuance (Purchase) of Equity Shares-62.76K
Issuance (Repayment) of Debt Securities -1000.00K
Net Cash Flow from Investing-600.00K
Net Cash Flow from Operations-1.30M
Share Based Compensation3.79M